Physician profile
Travis Frazier
NPI 1194790998
$1,141.08
in general payments reported to CMS, 2019-2025
11 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.01 · 2021: $20.61 · 2022: $57.98 · 2023: $284 · 2024: $383 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $583.81 | 2021-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Abbvie INC. | $176.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $76.50 | 2022-2023 | |
| Glaukos Corporation | $74.01 | 2019 | |
| Lilly USA, LLC | $70.32 | 2023-2024 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $34.61 | 2023-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.50 | 2024 | Spevigo |
| Janssen Biotech, INC. | $24.51 | 2024 | Tremfya |
| Bausch & Lomb Americas INC. | $24.25 | 2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $23.79 | 2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $18.77 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.